We are live on
!
Find out more
VanEck Associates Portfolio holdings
AUM
$133B
1-Year Est. Return
72.99%
This Fund
S&P 500
This Quarter
Est. Return
+3.56%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$21.3B
AUM Growth
+$580M
(+2.8%)
Cap. Flow
+$169M
Cap. Flow
% of AUM
0.79%
Top 10 Holdings %
Top 10 Hldgs %
35.94%
Holding
882
New
52
Increased
484
Reduced
289
Closed
51
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NGD
New Gold Inc
NGD
|
+$52.1M |
| 2 |
Veeva Systems
VEEV
|
+$37.6M |
| 3 |
UnitedHealth
UNH
|
+$36.1M |
| 4 |
ServiceNow
NOW
|
+$35.9M |
| 5 |
B
Barrick Mining
B
|
+$35.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$43.4M |
| 2 |
ESV
Ensco Rowan plc
ESV
|
+$38.4M |
| 3 |
Walt Disney
DIS
|
+$35.1M |
| 4 |
McKesson
MCK
|
+$34.8M |
| 5 |
Hershey
HSY
|
+$33.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Materials | 56.36% |
| 2 | Technology | 9.22% |
| 3 | Energy | 7.08% |
| 4 | Healthcare | 5.95% |
| 5 | Financials | 3.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Teva Pharmaceuticals
TEVA
$41.2B
| $4.66M | 0.02% |
677,300
-210,457
| -24% | -$1.61M |
|
352
Occidental Petroleum
OXY
$55.6B
| $4.6M | 0.02% |
103,443
+6,251
| +6% | +$296K |
|
353
Neogen
NEOG
$2.51B
| $4.58M | 0.02% |
134,356
+1,532
| +1% | +$53K |
|
354
Linde
LIN
$235B
| $4.43M | 0.02% |
22,890
-480
| -2% | -$93K |
|
355
Wolfspeed
WOLF
$1.24B
| $4.38M | 0.02% |
89,374
+10,256
| +13% | +$558K |
|
356
PennantPark Floating Rate Capital
PFLT
$696M
| $4.33M | 0.02% |
373,176
+9,560
| +3% | +$111K |
|
|
DO
357
DELISTED
Diamond Offshore Drilling
DO
| $4.31M | 0.02% |
775,914
-700,937
| -47% | -$5.12M |
|
358
iShares Russell 1000 Value ETF
IWD
$81.8B
| $4.27M | 0.02% |
33,258
+8,591
| +35% | +$1.09M |
|
359
Elevance Health
ELV
$81.6B
| $4.25M | 0.02% |
17,698
+557
| +3% | +$153K |
|
360
Healthpeak Properties
DOC
$15.2B
| $4.23M | 0.02% |
118,710
+6,421
| +6% | +$217K |
|
361
Jazz Pharmaceuticals
JAZZ
$16.2B
| $4.23M | 0.02% |
33,014
-18,847
| -36% | -$2.53M |
|
|
BCPC
362
Balchem Corp
BCPC
$5.23B
| $4.18M | 0.02% |
42,159
+943
| +2% | +$89.9K |
|
|
GPMT
363
Granite Point Mortgage Trust
GPMT
$64.7M
| $4.18M | 0.02% |
222,858
-6,697
| -3% | -$126K |
|
364
Alexandria Real Estate Equities
ARE
$9.15B
| $4.17M | 0.02% |
27,058
+972
| +4% | +$144K |
|
365
IBM
IBM
$209B
| $4.15M | 0.02% |
29,837
+419
| +1% | +$56.5K |
|
|
NE
366
DELISTED
Noble Corporation
NE
| $4.03M | 0.02% |
3,172,280
-1,516,121
| -32% | -$2.59M |
|
367
Boeing
BA
$175B
| $4M | 0.02% |
10,507
+148
| +1% | +$52.9K |
|
368
Netflix
NFLX
$305B
| $3.98M | 0.02% |
148,620
+4,720
| +3% | +$148K |
|
|
ARR
369
Armour Residential REIT
ARR
$2.33B
| $3.97M | 0.02% |
47,456
-5,588
| -11% | -$488K |
|
370
NewtekOne
NEWT
$423M
| $3.96M | 0.02% |
175,209
+4,904
| +3% | +$109K |
|
371
Gladstone Investment Corp
GAIN
$646M
| $3.9M | 0.02% |
315,913
+8,096
| +3% | +$94.3K |
|
372
United Therapeutics
UTHR
$26.2B
| $3.9M | 0.02% |
48,836
-5,512
| -10% | -$444K |
|
373
USA Compression Partners
USAC
$3.79B
| $3.85M | 0.02% |
222,635
+11,201
| +5% | +$190K |
|
374
General Motors
GM
$80B
| $3.83M | 0.02% |
102,133
+1,436
| +1% | +$55.2K |
|
375
Suburban Propane Partners
SPH
$1.23B
| $3.8M | 0.02% |
160,946
+8,098
| +5% | +$191K |
|
Similar funds
VanEck Associates's Q3 2019 Portfolio in Review
As of Q3 2019, VanEck Associates held 882 positions worth $21.3B, up 2.8% from $20.8B the previous quarter. Its ten largest holdings account for 36% of the portfolio.
VanEck Associates's Q3 2019 filing shows 52 new, 484 increased, 289 reduced and 51 closed positions. Its largest new stake was Veeva Systems: 234,351 shares worth $35.8M. The largest sale was Allergan plc, an estimated $43.4M.
By sector, the portfolio is most concentrated in Materials at 56% of assets, up from 55% a quarter earlier, followed by Technology and Energy.
- VanEck Associates's largest Q3 2019 buy was Veeva Systems: 234,351 shares worth $35.8M.
- VanEck Associates added most to New Gold Inc in Q3 2019, an estimated $52.1M increase.
- VanEck Associates's biggest Q3 2019 reduction was Allergan plc, cutting an estimated $43.4M.
- VanEck Associates fully exited Ensco Rowan plc in Q3 2019, selling an estimated $38.4M.
- VanEck Associates's ten largest holdings make up 36% of its $21.3B portfolio in Q3 2019.
- VanEck Associates opened 52 new positions and closed 51 in Q3 2019.
- VanEck Associates's portfolio value rose 2.8% quarter-over-quarter to $21.3B.
Based on VanEck Associates's 13F filing for Q3 2019, filed 8 Nov 2019.